Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: Subanalysis from the JPAD trial

Diabetes Care

Volumn 34, Issue 2, 2011, Pages 280-285

  Saito, Yoshihiko ^a   Morimoto, Takeshi ^b   Ogawa, Hisao ^c   Nakayama, Masafumi ^c   Uemura, Shiro ^a   Doi, Naofumi ^a   Jinnouchi, Hideaki ^d   Waki, Masako ^e   Soejima, Hirofumi ^c   Sugiyama, Seigo ^c   Okada, Sadanori ^a   Akai, Yasuhiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Jinnouch Hospital   (Japan)

^e SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ATHEROSCLEROSIS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 79951712417     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1615     Document Type: Article

References (23)

1. Pignone M, Alberts MJ, Colwell JA, et al.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395-1402
2. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-636 (Pubitemid 32322240)
3. Anavekar NS, Solomon SD, McMurray JJ, et al. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. Am J Cardiol 2008;101:925-929
4. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103:88-92
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1):S1-S266
6. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-1304
7. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-135
8. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-316 (Pubitemid 18042841)
9. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl. 1):S13-S61
10. Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141
11. Belch J, MacCuish A, Campbell I, et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arteial diseases. Br Med J 2008;337:a1840
12. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
13. Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860
14. Matsuo S, Imai E, Horio M, et al.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992
15. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13:621-630
16. Beauvieux MC, Le Moigne F, Lasseur C, et al. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care 2007;30: 1988-1994 (Pubitemid 47219405)
17. Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 2006;29:1024-1030 (Pubitemid 44115239)
18. Shiba N, Matsuki M, Takahashi J, Tada T, Watanabe J, Shimokawa H. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008;72:173-178 (Pubitemid 351413351)
19. Bulckaen H, Prévost G, Boulanger E, et al. Low-dose aspirin prevents age-related endothelial dysfunction in amouse model of physiological aging. Am J Physiol Heart Circ Physiol 2008;294:H1562-H1570 (Pubitemid 351490585)
20. Signori LU, da Silva AM, Plentz RD, Moreno H Jr, Irigoyen MC, Schaan BD. Reversal of postprandial endothelial dysfunction by cyclooxygenase inhibition in healthy volunteers. J Cardiovasc Pharmacol 2009;54:90-93
21. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014-3019 (Pubitemid 350223637)
22. Lee PY, ChenWH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-727
23. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a posthoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56:956-965